ACAD
Price
$17.12
Change
-$0.29 (-1.67%)
Updated
Dec 18, 04:05 PM (EDT)
75 days until earnings call
VRTX
Price
$450.05
Change
-$19.19 (-4.09%)
Updated
Dec 18, 04:35 PM (EDT)
55 days until earnings call
Ad is loading...

ACAD vs VRTX

Header iconACAD vs VRTX Comparison
Open Charts ACAD vs VRTXBanner chart's image
ACADIA Pharmaceuticals
Price$17.12
Change-$0.29 (-1.67%)
Volume$1.3K
CapitalizationN/A
Vertex Pharmaceuticals
Price$450.05
Change-$19.19 (-4.09%)
Volume$1.3K
CapitalizationN/A
ACAD vs VRTX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. VRTX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and VRTX is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ACAD: $17.41 vs. VRTX: $469.24)
Brand notoriety: ACAD and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 84% vs. VRTX: 97%
Market capitalization -- ACAD: $2.9B vs. VRTX: $120.84B
ACAD [@Biotechnology] is valued at $2.9B. VRTX’s [@Biotechnology] market capitalization is $120.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileVRTX’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • VRTX’s FA Score: 1 green, 4 red.
According to our system of comparison, VRTX is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • VRTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -6.04% price change this week, while VRTX (@Biotechnology) price change was +0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 03, 2025.

VRTX is expected to report earnings on Feb 11, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($121B) has a higher market cap than ACAD($2.9B). VRTX has higher P/E ratio than ACAD: VRTX (32.76) vs ACAD (22.32). VRTX YTD gains are higher at: 15.324 vs. ACAD (-44.395). VRTX has higher annual earnings (EBITDA): 518M vs. ACAD (125M). VRTX has more cash in the bank: 6.52B vs. ACAD (565M). ACAD has less debt than VRTX: ACAD (49.4M) vs VRTX (1.7B). VRTX has higher revenues than ACAD: VRTX (10.6B) vs ACAD (929M).
ACADVRTXACAD / VRTX
Capitalization2.9B121B2%
EBITDA125M518M24%
Gain YTD-44.39515.324-290%
P/E Ratio22.3232.7668%
Revenue929M10.6B9%
Total Cash565M6.52B9%
Total Debt49.4M1.7B3%
FUNDAMENTALS RATINGS
ACAD vs VRTX: Fundamental Ratings
ACAD
VRTX
OUTLOOK RATING
1..100
1678
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
3489
PRICE GROWTH RATING
1..100
5454
P/E GROWTH RATING
1..100
9937
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (69) in the Biotechnology industry is in the same range as VRTX (77). This means that ACAD’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for ACAD (100). This means that VRTX’s stock grew significantly faster than ACAD’s over the last 12 months.

ACAD's SMR Rating (34) in the Biotechnology industry is somewhat better than the same rating for VRTX (89). This means that ACAD’s stock grew somewhat faster than VRTX’s over the last 12 months.

ACAD's Price Growth Rating (54) in the Biotechnology industry is in the same range as VRTX (54). This means that ACAD’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's P/E Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for ACAD (99). This means that VRTX’s stock grew somewhat faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADVRTX
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 7 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
55%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
61%
Declines
ODDS (%)
Bearish Trend 7 days ago
73%
Bearish Trend 6 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
59%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ITOS7.69-0.08
-1.03%
iTeos Therapeutics
IT497.42-5.16
-1.03%
Gartner
VMI326.32-5.15
-1.55%
Valmont Industries
MEG17.51-0.56
-3.10%
Montrose Environmental Group
RFIL3.75-0.16
-4.09%
RF Industries Ltd

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+0.40%
VRTX - ACAD
46%
Loosely correlated
+0.25%
FOLD - ACAD
43%
Loosely correlated
-0.10%
CCCC - ACAD
43%
Loosely correlated
-6.03%
PRTA - ACAD
42%
Loosely correlated
+11.34%
DNLI - ACAD
41%
Loosely correlated
-0.30%
More

VRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with CCCC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRTX
1D Price
Change %
VRTX100%
+0.25%
CCCC - VRTX
39%
Loosely correlated
-6.03%
STTK - VRTX
37%
Loosely correlated
+5.50%
TECH - VRTX
37%
Loosely correlated
-1.17%
GMAB - VRTX
35%
Loosely correlated
+0.05%
REGN - VRTX
34%
Loosely correlated
+2.09%
More